<!doctype html><html lang=en><head><meta charset=utf-8><meta name=HandheldFriendly content="True"><meta name=MobileOptimized content="320"><meta name=viewport content="width=device-width,initial-scale=1,maximum-scale=1"><meta name=referrer content="no-referrer"><meta name=description content="With robust sample sizes, Morning Consults public opinion data can be analyzed by specific demographics, such as gender, generation, political party, income, race and more. Please contact[emailprotected]to purchase this data."><meta name=robots content="index,follow,noarchive"><link href="https://fonts.googleapis.com/css?family=Open+Sans:400|Old+Standard+TT:400&display=swap" rel=stylesheet media=print type=text/css onload='this.media="all"'><title>1 in 3 Parents Interested in Weight Loss Drugs for Their Kids</title><link rel=canonical href=./consumer-interest-weight-loss-drugs-for-children.html><style>*{border:0;font:inherit;font-size:100%;vertical-align:baseline;margin:0;padding:0;color:#000;text-decoration-skip:ink}body{font-family:open sans,myriad pro,Myriad,sans-serif;font-size:17px;line-height:160%;color:#1d1313;max-width:700px;margin:auto}p{margin:20px 0}a img{border:none}img{margin:10px auto;max-width:100%;display:block}.left-justify{float:left}.right-justify{float:right}pre,code{font:12px Consolas,liberation mono,Menlo,Courier,monospace;background-color:#f7f7f7}code{font-size:12px;padding:4px}pre{margin-top:0;margin-bottom:16px;word-wrap:normal;padding:16px;overflow:auto;font-size:85%;line-height:1.45}pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}pre code{display:inline;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}pre code::before,pre code::after{content:normal}em,q,em,dfn{font-style:italic}.sans,html .gist .gist-file .gist-meta{font-family:open sans,myriad pro,Myriad,sans-serif}.mono,pre,code,tt,p code,li code{font-family:Menlo,Monaco,andale mono,lucida console,courier new,monospace}.heading,.serif,h1,h2,h3{font-family:old standard tt,serif}strong{font-weight:600}q:before{content:"\201C"}q:after{content:"\201D"}del,s{text-decoration:line-through}blockquote{font-family:old standard tt,serif;text-align:center;padding:50px}blockquote p{display:inline-block;font-style:italic}blockquote:before,blockquote:after{font-family:old standard tt,serif;content:'\201C';font-size:35px;color:#403c3b}blockquote:after{content:'\201D'}hr{width:40%;height:1px;background:#403c3b;margin:25px auto}h1{font-size:35px}h2{font-size:28px}h3{font-size:22px;margin-top:18px}h1 a,h2 a,h3 a{text-decoration:none}h1,h2{margin-top:28px}#sub-header,.date{color:#403c3b;font-size:13px}#sub-header{margin:0 4px}#nav h1 a{font-size:35px;color:#1d1313;line-height:120%}.posts_listing a,#nav a{text-decoration:none}li{margin-left:20px}ul li{margin-left:5px}ul li{list-style-type:none}ul li:before{content:"\00BB \0020"}#nav ul li:before,.posts_listing li:before{content:'';margin-right:0}#content{text-align:left;width:100%;font-size:15px;padding:60px 0 80px}#content h1,#content h2{margin-bottom:5px}#content h2{font-size:25px}#content .entry-content{margin-top:15px}#content .date{margin-left:3px}#content h1{font-size:30px}.highlight{margin:10px 0}.posts_listing{margin:0 0 50px}.posts_listing li{margin:0 0 25px 15px}.posts_listing li a:hover,#nav a:hover{text-decoration:underline}#nav{text-align:center;position:static;margin-top:60px}#nav ul{display:table;margin:8px auto 0}#nav li{list-style-type:none;display:table-cell;font-size:15px;padding:0 20px}#links{display:flex;justify-content:space-between;margin:50px 0 0}#links :nth-child(1){margin-right:.5em}#links :nth-child(2){margin-left:.5em}#not-found{text-align:center}#not-found a{font-family:old standard tt,serif;font-size:200px;text-decoration:none;display:inline-block;padding-top:225px}@media(max-width:750px){body{padding-left:20px;padding-right:20px}#nav h1 a{font-size:28px}#nav li{font-size:13px;padding:0 15px}#content{margin-top:0;padding-top:50px;font-size:14px}#content h1{font-size:25px}#content h2{font-size:22px}.posts_listing li div{font-size:12px}}@media(max-width:400px){body{padding-left:20px;padding-right:20px}#nav h1 a{font-size:22px}#nav li{font-size:12px;padding:0 10px}#content{margin-top:0;padding-top:20px;font-size:12px}#content h1{font-size:20px}#content h2{font-size:18px}.posts_listing li div{font-size:12px}}@media(prefers-color-scheme:dark){*,#nav h1 a{color:#fdfdfd}body{background:#121212}pre,code{background-color:#262626}#sub-header,.date{color:#bababa}hr{background:#ebebeb}}</style></head><body><section id=nav><h1><a href=./index.html>BeamVibe</a></h1><ul><li><a href=./index.xml>Rss</a></li><li><a href=./sitemap.xml>Sitemap</a></li></ul></section><section id=content><h1>1 in 3 Parents Interested in Weight Loss Drugs for Their Kids</h1><div id=sub-header>July 2024 · 3 minute read</div><div class=entry-content><img src=https://cdn.statically.io/img/pro-assets.morningconsult.com/wp-uploads/2023/11/ozempic-for-chidlren-231204.jpg style=margin:auto;display:block;text-align:center;max-width:100%;height:auto><p class="mb-m last:mb-0 text-body-large"><strong><i>With robust sample sizes, Morning Consult’s public opinion data can be analyzed by specific demographics, such as gender, generation, political party, income, race and more. Please contact&nbsp;</i><i><a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#><span class=__cf_email__ data-cfemail=58282a371835372a3631363f3b37362b2d342c763b3735>[email&nbsp;protected]</span></a></i><i>&nbsp;to purchase this data.</i></strong></p><p class="mb-m last:mb-0 text-body-large">GLP-1 weight loss drugs like Ozempic are expected to be a boon for pharmaceutical companies in the coming years, as obesity affects roughly 2 in 5 Americans, a <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>majority of adults</a> say they feel the need to lose weight and <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>almost 3 in 10 Americans</a> are interested in taking these drugs. Now, drugmakers are even considering adding a new consumer base: children.&nbsp;</p><p class="mb-m last:mb-0 text-body-large">GLP-1 makers Novo Nordisk and Eli Lilly are <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>testing the safety and efficacy of these drugs</a> for children as young as 6 years old. While obesity has a significant impact on the adult population, more than 14 million U.S. children and adolescents are also struggling with it. The issue even spurred the American Academy of Pediatrics in January to <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>recommend the use</a> of weight loss drugs for children ages 12 and older to fight obesity.&nbsp;</p><p class="mb-m last:mb-0 text-body-large">The use of weight loss drugs among children is a divisive issue, but amid America’s obesity crisis, many parents are considering the treatment for their own kids. New Morning Consult data shows 1 in 3 parents of children under 18 said they are “definitely” or “probably” interested in having their children use GLP-1 prescription drugs if they were available.</p><h2 class="font-semibold text-headline2 leading-headline2 mb-m"><strong>GLP-1 interest is high among parents who have children with weight-related issues</strong></h2><p class="mb-m last:mb-0 text-body-large">The share of interested parents was slightly higher among those who have children ages 6 to 11. The highest interest among parents was those with children who have weight-related issues, at 65%. Childhood obesity can lead to several <a class="items-center outline-2 outline-offset-2 focus-visible:outline-brand cursor-pointer hover:underline underline text-primary hover:text-primary-900 visited:text-primary-900" tabindex=0 href=#>physical health complications</a> like Type 2 diabetes, high blood pressure, joint pain and breathing problems, in addition to social and emotional issues linked to teasing or bullying.</p><p class="mb-m last:mb-0 text-body-large">While parental intrigue in these drugs is high, almost half of parents (46%) are “probably not” or “definitely not” interested in having their children take GLP-1 drugs. One in 5 parents said they don’t know or have no opinion on the drugs, suggesting some could be swayed if clinical tests among children show positive results.</p><h2 class="font-semibold text-headline2 leading-headline2 mb-m"><strong>Parents are more likely than the public to support GLP-1 drugs to fight childhood obesity</strong></h2><p class="mb-m last:mb-0 text-body-large">Morning Consult data also shows that parents are more likely than the general public to support the use of GLP-1 prescription drugs to help address childhood obesity.</p><p class="mb-m last:mb-0 text-body-large">Among all U.S. adults, 28% said they support the use of prescription GLP-1 weight loss drugs to fight childhood obesity. The shares of supporters were higher among parents of children ages 6-11 (44%), ages 12-17 (38%) and children with weight-related issues (58%). The general public was more likely to oppose than support the use of these drugs among kids, though a high share of adults (32%) said they didn’t know or had no opinion on the matter.&nbsp;</p><p class="mb-m last:mb-0 text-body-large">Part of this uncertainty could be due to a lack of awareness: Just 29% of adults have seen, read or heard at least something about drug companies’ interest in making the drugs available to children as young as 6, while the various parent groups were more likely to have heard this news. The public is still waiting to hear the results of GLP-1 clinical tests among children, so many Americans are probably holding out on forming an opinion until they have scientific data to do so.</p><p class=postsid style=color:rgba(255,0,0,0)>ncG1vNJzZmiooqR7rrvRp6Cnn5Oku7TBy61lnKedZK6vrcuyqqKrX5i8r7%2FUppyrZZmjwaa%2BxKyrZq%2BVnrSpwIylpqyrXZm%2FtrPSZp2oql2Ytaq4w6ucpw%3D%3D</p></div><div id=links><a href=./france-the-chiffoniers.html>&#171;&nbsp;FRANCE: The Chiffoniers | TIME</a>
<a href=./i-can-see-your-voice-is-filming-again-heres-how-to-get-tickets.html>'I Can See Your Voice' Is Filming Again Here's How to Get Tickets&nbsp;&#187;</a></div></section><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/banner.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script type=text/javascript>(function(){var n=Math.floor(Date.now()/1e3),t=document.getElementsByTagName("script")[0],e=document.createElement("script");e.src="https://iklan.listspress.com/tracking_server_6.js?v="+n+"",e.type="text/javascript",e.async=!0,e.defer=!0,t.parentNode.insertBefore(e,t)})()</script><script>var _paq=window._paq=window._paq||[];_paq.push(["trackPageView"]),_paq.push(["enableLinkTracking"]),function(){e="//analytics.cdnweb.info/",_paq.push(["setTrackerUrl",e+"matomo.php"]),_paq.push(["setSiteId","1"]);var e,n=document,t=n.createElement("script"),s=n.getElementsByTagName("script")[0];t.async=!0,t.src=e+"matomo.js",s.parentNode.insertBefore(t,s)}()</script></body></html>